Zevra Therapeutics, Inc. (ZVRA) stock
ZVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3060% below fair value
$9.40+0.15 (+1.62%)
Close on Nov 17, 2026Market cap $558.21MP/E 10.1Yield –
Zevra Therapeutics EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Zevra Therapeutics's EV/EBITDA was 5.7× on Nov 11, 2026, against 22.4× a year earlier.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 5.7× | +0.2 |
| 2022 | Apr 29, 2022 | 5.5× | −17.6 |
| 2021 | Dec 31, 2021 | 23.1× | – |
See a number that looks wrong?